Access to information about drugs is essential for the quality use of medicines. Pharmaceutical companies and regulatory agencies, such as the Therapeutic Goods Administration (TGA), hold large quantities of information about individual drugs, but do not always share this information. To encourage transparency,Australian Prescriberrates companies' willingness to provide clinical information about new drugs.Table 1shows how the companies have performed between January 2009 and December 2010.
The TGA is now publishing Australian Public Assessment Reports (AusPARs) for prescription medicines. While the Editorial Executive Committee welcomes this move to greater transparency, it will still ask companies to provide the clinical evaluations for their new products. While there are similarities, the AusPAR may not include all the details found in the regulator's clinical evaluation.
For 2011, the T-score has been revised to include the AusPAR.